← All trials
NCT04562467
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 24, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- May 1, 2021
- First posted
- Sep 24, 2020
- Last posted
- Sep 25, 2020
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Canadian Medical and Surgical Knowledge Translation Research GroupLead sponsor
- University of Western OntarioCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoCollaborator
- HLS Therapeutics, IncCollaborator
- Unity Health TorontoOverall official - principal investigator
- Unity Health TorontoCollaborator
- Harvard UniversityStudy chair
- University of Western OntarioOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.